AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26732142 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized hypertonic saline (3 mL, 4 times/day)
Number of subjects: 0
Study 26732142 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% saline, 3 mL, 4 times/day)
Number of subjects: 0
Study 26732142 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized hypertonic saline
Number of subjects: 0
Study 26732142 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 24508581 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behaviour therapy (CBT)
Number of subjects: 60
Study 24508581 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 60
Study 22397454 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 × week training (80% of maximum)
Number of subjects: 72
Study 22397454 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 × week training (80% and 50%)
Number of subjects: 72
Study 22397454 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 72
Study 20230419 — intervention group
Group type: EXPERIMENTAL
Intervention: Romiplostim
Number of subjects: 125
Study 20230419 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125
Study 17433898 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin supplementation (folic acid, pyridoxine, vitamin B12)
Number of subjects: 0
Study 17433898 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 15713727 — intervention group
Group type: EXPERIMENTAL
Intervention: 125 IU hCG
Number of subjects: 29
Study 15713727 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 IU hCG
Number of subjects: 29
Study 15713727 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 IU hCG
Number of subjects: 29
Study 15713727 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 29
Study 12390102 — intervention group
Group type: EXPERIMENTAL
Intervention: RAC (Rabeprazole + Amoxicillin + Clarithromycin)
Number of subjects: 295
Study 12390102 — intervention group
Group type: EXPERIMENTAL
Intervention: R20C400 (Rabeprazole 10 mg + Amoxicillin 750 mg + Clarithromycin 200 mg, twice daily)
Number of subjects: 295
Study 12390102 — intervention group
Group type: EXPERIMENTAL
Intervention: R40C400 (Rabeprazole 20 mg + Amoxicillin 750 mg + Clarithromycin 200 mg, twice daily)
Number of subjects: 295
Study 12390102 — intervention group
Group type: EXPERIMENTAL
Intervention: R40C800 (Rabeprazole 20 mg + Amoxicillin 750 mg + Clarithromycin 400 mg, twice daily)
Number of subjects: 295
Study 12390102 — intervention group
Group type: COMPARATOR
Intervention: LAC (Lansoprazole + Amoxicillin + Clarithromycin)
Number of subjects: 295
Study 9949744 — intervention group
Group type: EXPERIMENTAL
Intervention: Cash bonus for practice-wide increases
Number of subjects: 60
Study 9949744 — intervention group
Group type: COMPARATOR
Intervention: Enhanced fee for service
Number of subjects: 60
Study 9949744 — intervention group
Group type: COMPARATOR
Intervention: Feedback
Number of subjects: 60
Study 8775655 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive services intervention (workshops and individualized counseling on nutrition and exercise)
Number of subjects: 0
Study 1976543 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral PGE2 tablets
Number of subjects: 0
Study 1976543 — intervention group
Group type: COMPARATOR
Intervention: Intravenous oxytocin
Number of subjects: 0
Study 6988948 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative tinidazole added to pre-, per-, and postoperative doxycycline
Number of subjects: 0
Study 6988948 — intervention group
Group type: COMPARATOR
Intervention: Placebo added to pre-, per-, and postoperative doxycycline
Number of subjects: 0
Study 6988948 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinidazole
Number of subjects: 0
Study 6988948 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline
Number of subjects: 0
Study 31706886 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-coated balloon (DCB)
Number of subjects: 285
Study 31706886 — intervention group
Group type: COMPARATOR
Intervention: Control (uncoated balloon)
Number of subjects: 285
Study 31336497 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 g soy nut diet for 8 weeks
Number of subjects: 70
Study 31336497 — intervention group
Group type: COMPARATOR
Intervention: Usual diet of diabetes
Number of subjects: 70
Study 28801554 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed fractional dose regimen of the RTS,S malaria vaccine (0-1-7 month schedule, third dose at 20% of full dose)
Number of subjects: 0
Study 28801554 — intervention group
Group type: EXPERIMENTAL
Intervention: CSP-specific IgG1
Number of subjects: 0
Study 28801554 — intervention group
Group type: EXPERIMENTAL
Intervention: CSP-specific IgG4
Number of subjects: 0
Study 25459687 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary transplantation of CD34(+) cells
Number of subjects: 21
Study 25617561 — intervention group
Group type: EXPERIMENTAL
Intervention: Lemon verbena supplementation (10% w/w verbascoside)
Number of subjects: 30
Study 25617561 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 23067901 — intervention group
Group type: EXPERIMENTAL
Intervention: Trainee operator using transradial (TR) access
Number of subjects: 100
Study 23067901 — intervention group
Group type: EXPERIMENTAL
Intervention: Trainee operator using transfemoral (TF) access
Number of subjects: 100
Study 23067901 — intervention group
Group type: EXPERIMENTAL
Intervention: Expert operator using transradial (TR) access
Number of subjects: 100
Study 23067901 — intervention group
Group type: EXPERIMENTAL
Intervention: Expert operator using transfemoral (TF) access
Number of subjects: 100
Study 23067901 — intervention group
Group type: COMPARATOR
Intervention: Transfemoral (TF) access
Number of subjects: 100
Study 19579201 — intervention group
Group type: EXPERIMENTAL
Intervention: SprayShield™ Adhesion Barrier System
Number of subjects: 0
Study 19579201 — intervention group
Group type: COMPARATOR
Intervention: Good surgical technique (Control)
Number of subjects: 0
Study 17473089 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim/sulfamethoxazole (18 mg/kg, 2 times per day) for 6 to 12 weeks
Number of subjects: 101
Study 17473089 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study 15081178 — intervention group
Group type: EXPERIMENTAL
Intervention: Community consultation (CC) and public disclosure (PD) activities conducted by investigators
Number of subjects: 0
Study 15081178 — intervention group
Group type: EXPERIMENTAL
Intervention: IRB approval process
Number of subjects: 0
Study 11864862 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary magnesium intake less than 160 mg/d (less than half of the recommended dietary allowance)
Number of subjects: 22
Study 11864862 — intervention group
Group type: COMPARATOR
Intervention: Dietary magnesium intake of 320 mg/d (recommended dietary allowance)
Number of subjects: 22
Study 10753423 — intervention group
Group type: EXPERIMENTAL
Intervention: Arlevert therapy
Number of subjects: 122
Study 10753423 — intervention group
Group type: COMPARATOR
Intervention: dimenhydrinate
Number of subjects: 122
Study 10753423 — intervention group
Group type: COMPARATOR
Intervention: cinnarizine
Number of subjects: 122
Study 8561101 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid admission (1-day)
Number of subjects: 186
Study 8561101 — intervention group
Group type: COMPARATOR
Intervention: Slow admission (14-day)
Number of subjects: 186
Study 8561101 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid admission (1-day) and Slow admission (14-day)
Number of subjects: 186
Study 1977626 — intervention group
Group type: EXPERIMENTAL
Intervention: Elective hospitalization between 30-32 and 36 weeks of gestation
Number of subjects: 151
Study 1977626 — intervention group
Group type: COMPARATOR
Intervention: Control group 1: Not hospitalized, instructed to rest at home
Number of subjects: 151
Study 1977626 — intervention group
Group type: COMPARATOR
Intervention: Control group 2: Not hospitalized, not instructed to rest at home
Number of subjects: 151
Study 31588657 — intervention group
Group type: EXPERIMENTAL
Intervention: Rongliflozin (10-50 mg once daily for 12 days in T2DM)
Number of subjects: 86
Study 31588657 — intervention group
Group type: EXPERIMENTAL
Intervention: Rongliflozin (10-200 mg single ascending dose in healthy participants)
Number of subjects: 86
Study 31588657 — intervention group
Group type: EXPERIMENTAL
Intervention: Rongliflozin (20 mg with food in healthy participants)
Number of subjects: 86
Study 29406435 — intervention group
Group type: EXPERIMENTAL
Intervention: NIT-NASHs test
Number of subjects: 1081
Study 29406435 — intervention group
Group type: COMPARATOR
Intervention: NIT-NASHs test in control group
Number of subjects: 1081
Study 29406435 — intervention group
Group type: COMPARATOR
Intervention: NIT-NASHs test vs standard tests
Number of subjects: 1081
Study 29406435 — intervention group
Group type: EXPERIMENTAL
Intervention: NIT-NASHs combined with FibroTest
Number of subjects: 1081
Study 27565424 — intervention group
Group type: EXPERIMENTAL
Intervention: Pure water mouthwash
Number of subjects: 122
Study 27565424 — intervention group
Group type: EXPERIMENTAL
Intervention: Licorice mouthwash
Number of subjects: 122
Study 27565424 — intervention group
Group type: COMPARATOR
Intervention: No mouthwash (control)
Number of subjects: 122
Study 24862167 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline 1 mg twice daily
Number of subjects: 112
Study 24862167 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112
Study 22137672 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevelamer (n = 47)
Number of subjects: 100
Study 22137672 — intervention group
Group type: COMPARATOR
Intervention: Calcium acetate (n = 53)
Number of subjects: 100
Study 20638774 — intervention group
Group type: EXPERIMENTAL
Intervention: Global Postural Re-education (GPR)
Number of subjects: 52
Study 20638774 — intervention group
Group type: COMPARATOR
Intervention: Pelvic Floor Muscle Training (PFMT)
Number of subjects: 52
Study 17906188 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 days of massage therapy
Number of subjects: 10
Study 17906188 — intervention group
Group type: COMPARATOR
Intervention: 5 days without massage therapy
Number of subjects: 10
Study 16142136 — intervention group
Group type: EXPERIMENTAL
Intervention: Prépidil (prostaglandin gel)
Number of subjects: 0
Study 16142136 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 12046339 — intervention group
Group type: EXPERIMENTAL
Intervention: Saliva ferning test (SFT)
Number of subjects: 70
Study 10206605 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic lumbar extension exercises with pelvic restraint
Number of subjects: 12
Study 10206605 — intervention group
Group type: COMPARATOR
Intervention: Dynamic lumbar extension exercises without pelvic restraint
Number of subjects: 12
Study 7872941 — intervention group
Group type: EXPERIMENTAL
Intervention: Body Dysmorphic Disorder Examination (BDDE)
Number of subjects: 0
Study 2222274 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryotherapy
Number of subjects: 291
Study 2222274 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 291
Study 414129 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium nicotinate‐magnesium dehydrocholate
Number of subjects: 102
Study 414129 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study 31439323 — intervention group
Group type: EXPERIMENTAL
Intervention: active tcVNS
Number of subjects: 24
Study 31439323 — intervention group
Group type: COMPARATOR
Intervention: sham tcVNS
Number of subjects: 24
Study 31815642 — intervention group
Group type: EXPERIMENTAL
Intervention: Social skills group training (SSGT)
Number of subjects: 0
Study 31815642 — intervention group
Group type: COMPARATOR
Intervention: Active control groups
Number of subjects: 0
Study 28658164 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone hydrochloride 0.06 mg/kg (group A)
Number of subjects: 149
Study 28658164 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone hydrochloride 0.08 mg/kg (group B)
Number of subjects: 149
Study 28658164 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl 2 ug/kg (group C)
Number of subjects: 149
Study 25220387 — intervention group
Group type: COMPARATOR
Intervention: NB-UVB alone
Number of subjects: 27
Study 25220387 — intervention group
Group type: EXPERIMENTAL
Intervention: NB-UVB plus calcipotriol (0.005%)
Number of subjects: 27
Study 23681759 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg/kg praziquantel
Number of subjects: 151
Study 23681759 — intervention group
Group type: COMPARATOR
Intervention: 40 mg/kg praziquantel
Number of subjects: 151
Study 21495523 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil (3 mg daily)
Number of subjects: 21
Study 21495523 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 19629461 — intervention group
Group type: EXPERIMENTAL
Intervention: Grapefruit juice (GFJ) with FK506 (tacrolimus)
Number of subjects: 30
Study 19629461 — intervention group
Group type: COMPARATOR
Intervention: Standard FK506-based immunosuppressant regimen only (Control)
Number of subjects: 30
Study 16958739 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural mineral dietary supplement (NMDS), 1 l, swished twice a day
Number of subjects: 70
Study 16958739 — intervention group
Group type: COMPARATOR
Intervention: Placebo (de-ionized water), 1 l, swished twice a day
Number of subjects: 70
Study 16958739 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural mineral dietary supplement (NMDS)
Number of subjects: 70
Study 16958739 — intervention group
Group type: COMPARATOR
Intervention: Placebo (de-ionized water)
Number of subjects: 70
Study 12864878 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril treatment program
Number of subjects: 267
Study 12864878 — intervention group
Group type: COMPARATOR
Intervention: Historical controls (no treatment or inconsistent treatment)
Number of subjects: 267
Study 10695647 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal psychotherapy (IPT) and pharmacotherapy initiated at the outset of treatment
Number of subjects: 339
Study 10695647 — intervention group
Group type: COMPARATOR
Intervention: Interpersonal psychotherapy (IPT) alone first, then combination therapy for non-remitters
Number of subjects: 339
Study 9350017 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcuticular suture
Number of subjects: 0
Study 9350017 — intervention group
Group type: COMPARATOR
Intervention: Staples
Number of subjects: 0
Study 8165074 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole cow milk
Number of subjects: 104
Study 8165074 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard infant formula (48% to 49% of energy as fat from butterfat)
Number of subjects: 104
Study 8165074 — intervention group
Group type: COMPARATOR
Intervention: Lower fat follow-up formulas (36% kcal from a fat blend of palm olein, corn, and safflower oils)
Number of subjects: 104
Study 3215161 — intervention group
Group type: EXPERIMENTAL
Intervention: Relapse-prevention (RP) treatment
Number of subjects: 0
Study 3215161 — intervention group
Group type: COMPARATOR
Intervention: Traditional treatment program (AA)
Number of subjects: 0
Study 3215161 — intervention group
Group type: COMPARATOR
Intervention: Self-help formats
Number of subjects: 0
Study 3215161 — intervention group
Group type: COMPARATOR
Intervention: Group-based treatment
Number of subjects: 0
Study 30742471 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy (CPT)
Number of subjects: 117
Study 30742471 — intervention group
Group type: COMPARATOR
Intervention: Non-trauma-focused supportive psychotherapy
Number of subjects: 117
Study 30742471 — intervention group
Group type: COMPARATOR
Intervention: CPT vs Non-trauma-focused psychotherapy
Number of subjects: 117
Study 29258724 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral radiocontrast ingestion
Number of subjects: 20
Study 29258724 — intervention group
Group type: COMPARATOR
Intervention: No oral radiocontrast (baseline)
Number of subjects: 20
Study 23632471 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Participation-Based Dietary Intervention (PPDI)
Number of subjects: 56
Study 23632471 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 56
Study 22421690 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly antibiotic treatment (ciprofloxacin or azithromycin) for 9 months
Number of subjects: 636
Study 22421690 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment for 9 months
Number of subjects: 636
Study 20027030 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracervical block with 1% lidocaine
Number of subjects: 80
Study 20027030 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 80
Study 18272959 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril-based blood pressure lowering
Number of subjects: 1757
Study 18272959 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1757
Study 15745773 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilocarpine 2%
Number of subjects: 66
Study 15745773 — intervention group
Group type: COMPARATOR
Intervention: Near-point accommodation
Number of subjects: 66
Study 15745773 — intervention group
Group type: COMPARATOR
Intervention: Control IOLs
Number of subjects: 66
Study 15745773 — intervention group
Group type: EXPERIMENTAL
Intervention: DCNVA
Number of subjects: 66
Study 14519709 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (250 mg for weight <40 kg or 500 mg for weight ≥40 kg) administered orally 3 days a week for 168 days
Number of subjects: 185
Study 14519709 — intervention group
Group type: COMPARATOR
Intervention: Placebo (identically packaged tablets)
Number of subjects: 185
Study 14519709 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 185
Study 10661703 — intervention group
Group type: EXPERIMENTAL
Intervention: Saphenous vein patch angioplasty
Number of subjects: 66
Study 8949693 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast milk
Number of subjects: 58
Study 8949693 — intervention group
Group type: EXPERIMENTAL
Intervention: Preterm formula supplemented with LCP (PF‐LCP)
Number of subjects: 58
Study 8949693 — intervention group
Group type: COMPARATOR
Intervention: Traditional preterm formula (PF)
Number of subjects: 58
Study 8949693 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast milk and PF‐LCP
Number of subjects: 58
Study 8949693 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (breast milk, PF‐LCP, PF)
Number of subjects: 58
Study 1851785 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined potassium‐losing and ‐sparing diuretic (triamterene 50 mg plus hydrochlorothiazide 25 mg)
Number of subjects: 1000
Study 1851785 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1000
Study 7226124 — intervention group
Group type: EXPERIMENTAL
Intervention: CDVFP (cyclophosphamide, doxorubicin, vincristine, fluorouracil, and prednisone)
Number of subjects: 0
Study 7226124 — intervention group
Group type: EXPERIMENTAL
Intervention: CDVFP + MER (0.4 mg S.C. every four weeks)
Number of subjects: 0
Study 7226124 — intervention group
Group type: EXPERIMENTAL
Intervention: CD/MF (CD alternating with methotrexate and fluorouracil)
Number of subjects: 0
Study 7226124 — intervention group
Group type: EXPERIMENTAL
Intervention: CD/MF + MER (0.4 mg S.C. every four weeks)
Number of subjects: 0
Study 7226124 — intervention group
Group type: COMPARATOR
Intervention: Control group (no immunotherapy)
Number of subjects: 0
Study 31099929 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 1 implant placement
Number of subjects: 46
Study 31099929 — intervention group
Group type: COMPARATOR
Intervention: Type 2 implant placement
Number of subjects: 46
Study 28577933 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective reporting of antibiotic susceptibility test (AST) results
Number of subjects: 131
Study 28577933 — intervention group
Group type: COMPARATOR
Intervention: Complete reporting of AST results
Number of subjects: 131
Study 28577933 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective reporting of AST results
Number of subjects: 131
Study 26438056 — intervention group
Group type: EXPERIMENTAL
Intervention: Movement-to-music video program (exercise every other day for 7 weeks)
Number of subjects: 0
Study 26438056 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 24144717 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviews (MIs) - 5 family meetings
Number of subjects: 372
Study 24144717 — intervention group
Group type: COMPARATOR
Intervention: Usual Care - information leaflet
Number of subjects: 372
Study 24144717 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviews (MIs)
Number of subjects: 372
Study 21338903 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexually active adolescents (60% of the population) reporting four or more partners
Number of subjects: 1576
Study 21338903 — intervention group
Group type: EXPERIMENTAL
Intervention: Demographics, violence, and substance use correlates
Number of subjects: 1576
Study 21338903 — intervention group
Group type: EXPERIMENTAL
Intervention: Dating violence
Number of subjects: 1576
Study 21338903 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer violence and weapon carriage
Number of subjects: 1576
Study 21338903 — intervention group
Group type: EXPERIMENTAL
Intervention: Binge drinking and marijuana use
Number of subjects: 1576
Study 19697206 — intervention group
Group type: EXPERIMENTAL
Intervention: Superficial injection of local anaesthetic prior to deep injection into the cervix
Number of subjects: 60
Study 19697206 — intervention group
Group type: COMPARATOR
Intervention: Deep injection into the substance of the cervix (Control)
Number of subjects: 60
Study 18389594 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (Ursosan), 3-month course of treatment
Number of subjects: 0
Study 15244027 — intervention group
Group type: EXPERIMENTAL
Intervention: Female speech
Number of subjects: 20
Study 15244027 — intervention group
Group type: EXPERIMENTAL
Intervention: Male speech
Number of subjects: 20
Study 11139541 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated charcoal (5 g, four times a day, starting 3 hours after pill intake on cycle days 12, 13, and 14)
Number of subjects: 11
Study 11139541 — intervention group
Group type: COMPARATOR
Intervention: Control cycle (no activated charcoal)
Number of subjects: 11
Study 9646889 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 242
Study 9646889 — intervention group
Group type: COMPARATOR
Intervention: Sertraline
Number of subjects: 242